Three-dimensional recognition requirements for angiotensin agonists: a novel solution for an old problem

Area of Science:

• Medicinal Chemistry
• Molecular Pharmacology
• Structural Biology

Background:

• Angiotensin II (AT) plays a crucial role in cardiovascular regulation.
• Determining the biologically active conformation of AT is essential for understanding its receptor interactions.
• Existing knowledge on AT conformation is limited, hindering rational drug design.

Purpose of the Study:

• To determine the receptor-bound conformation of Angiotensin II (AT).
• To utilize this conformational model for designing novel AT receptor ligands.
• To validate the proposed model through the synthesis and testing of a new AT analog.

Main Methods:

• Computational analysis of low-energy conformers of AT and its analogs.
• Identification of key pharmacophoric groups (aromatic moieties and C-terminal carboxyl).
• Geometrical comparison of conformers to derive a receptor-bound model.

Main Results:

• A model for the receptor-bound conformation of AT was established.
• This model is consistent with known cyclic AT analogs exhibiting receptor binding.
• A novel analog, [D-Tyr4, Pro5]-AT, was designed based on the proposed conformation.
• The new analog exhibited significant affinity for AT receptors (IC50 = 42.8 nM).

Conclusions:

• The study successfully elucidated the receptor-bound conformation of Angiotensin II.
• The developed conformational model provides a basis for designing potent AT receptor modulators.
• The novel analog validates the proposed model and demonstrates potential therapeutic applications.